BRAF and colorectal carcinoma: Our previous clinical trials with BRAF-targeted therapy combinations in BRAFV600E CRC suggested potential links between BRAF pathway inhibition and the immune response12, including durable benefit lasting >1 year in roughly one third of patients with BRAFV600E CRC also harboring MSI.